THE FIRST-IN-CLASSBIOMIMETIC TAVR VALVE SHAPED FOR NATIVE PERFORMANCE
At Anteris Technologies, we are committed to discovering, developing, and delivering innovative solutions for significant challenges facing heart patients and their physicians. We're currently focused on developing a novel, first-in-class biomimetic transcatheter aortic valve replacement (TAVR) for the treatment of aortic stenosis. The DurAVR™ TAVR system is currently in the clinical trial phase of development. Learn more about the technology below.
DurAVR™ THV is a novel first-in-class biomimetic valve made from a single piece of native-shaped tissue. It’s designed to mimic the performance of a pre-disease human aortic valve. Early data from the company’s First-in-Human clinical study show excellent haemodynamic performance at 12 months.
ADAPT® ANTI-CALCIFICATION TISSUE
ADAPT®is Anteris’ patented anti-calcification tissue technology. ADAPT® tissue has been used clinically for over 10 years and distributed for use in over 50,000 patients worldwide.
ComASUR™ DELIVERY SYSTEM
The balloon expandable ComASUR™ Delivery System provides controlled deployment and accurate placement of the DurAVR™ THV valve, designed to achieve precise alignment with the heart’s native commissures to achieve ideal valve positioning.